247 related articles for article (PubMed ID: 29738778)
1. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
[TBL] [Abstract][Full Text] [Related]
2. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
4. [Combination of shikonin and gefitinib reverses drug resistance in human non-small cell lung cancer and its mechanism].
Ai XY; Hou XF; Feng NP
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(1):175-184. PubMed ID: 38403350
[TBL] [Abstract][Full Text] [Related]
5. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Feng C; Liu X; Li X; Guo F; Huang C; Qin Q; Wang Y
Oncol Rep; 2016 Jun; 35(6):3460-70. PubMed ID: 27109760
[TBL] [Abstract][Full Text] [Related]
8. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway.
Li B; Yuan Z; Jiang J; Rao Y
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490
[TBL] [Abstract][Full Text] [Related]
13. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
Li Q; Zhang D; Chen X; He L; Li T; Xu X; Li M
Sci Rep; 2015 Nov; 5():16082. PubMed ID: 26542452
[TBL] [Abstract][Full Text] [Related]
14. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Zhao XM; Pan SY; Huang QL; Lu YN; Wu XH; Chang JH; Liu ZB; Cai XW; Liu Q; Wang JL; Fu XL
Oncotarget; 2016 Aug; 7(31):49384-49396. PubMed ID: 27283902
[TBL] [Abstract][Full Text] [Related]
15. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
17. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
18. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
19. Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells.
Kim HJ; Hwang KE; Park DS; Oh SH; Jun HY; Yoon KH; Jeong ET; Kim HR; Kim YS
J Transl Med; 2017 May; 15(1):123. PubMed ID: 28569199
[TBL] [Abstract][Full Text] [Related]
20. Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway.
Liu B; Jin J; Zhang Z; Zuo L; Jiang M; Xie C
Biochem Cell Biol; 2019 Aug; 97(4):397-405. PubMed ID: 30475643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
